Avalo Therapeutics (C6K0) AI Stock Analysis

0 Followers

Avalo Therapeutics

(Frankfurt:C6K0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low Current LeverageLow current leverage reduces near-term solvency pressure and preserves more financial flexibility than a heavily indebted development-stage biotech would have. This may help AVTX direct available resources toward clinical programs and manage obligations while it works toward future revenue generation.

Negative Factors

Sharp Revenue DeclineSharp historical revenue contraction and minimal current revenue show that AVTX has not yet established a dependable commercial income stream. Continued dependence on investigational programs makes financial performance highly sensitive to clinical progress and delays the ability to fund operations internally.

Avalo Therapeutics (C6K0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 388.82M
Dividend Yield: ―
Average Volume (3M): 100
Price to Earnings (P/E): -1.5
Beta (1Y): 0.74
Revenue Growth: -87.53%
EPS Growth: 21.12%
Country: Germany
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Avalo Therapeutics Business Overview & Revenue Model

Company Description

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunolo...

Avalo Therapeutics Risk Analysis

Avalo Therapeutics disclosed 80 risk factors in its most recent earnings report. Avalo Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Q2, 2026

Avalo Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:C6K0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MIST	46Neutral	$89.78M	-1.10	-288.36%	―	―	21.42%
CRBP	45Neutral	$75.72M	-0.60	-87.05%	―	―	-29.66%
GUTS	43Neutral	$12.50M	-0.07	-1625.88%	―	-100.00%	46.66%
ELTX	40Underperform	$43.07M	-0.71	-1266.43%	―	―	49.43%

* Healthcare Sector Average

Performance Comparison

DE:C6K0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:C6K0	Avalo Therapeutics, Inc.	6.21	-7.87	-55.89%
CRBP	Corbus Pharmaceuticals Holdings	3.57	-6.87	-65.80%
MIST	Milestone Pharmaceuticals	0.77	-0.95	-55.12%
ELTX	Elicio Therapeutics, Inc	1.56	-7.51	-82.80%
GUTS	Fractyl Health, Inc.	0.97	-12.11	-92.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Avalo Therapeutics AI Stock Analysis